Navigation Links
Caliper Life Sciences' Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
Date:4/28/2008

- IVIS Imaging System Provides Real-Time Insight on Viability of Infectious

Disease Treatment Options -

HOPKINTON, Mass., April 28 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced that the Texas A&M Health Science Center Research Foundation (HSCRF) is using the IVIS Spectrum imaging system to speed the development of more effective therapeutic treatments for tuberculosis. Research efforts and the purchase of the IVIS system are funded through a grant to the Texas A&M Health Science Center from the Bill & Melinda Gates Foundation.

Tuberculosis currently affects nearly one-third of the world's population and remains a global threat due to severe and drug-resistant strains. According to the World Health Organization, tuberculosis is one of the most serious infectious diseases in the world. Caliper is dedicated to assisting the global fight against infectious diseases and aiding the discovery of life-saving treatments.

Researchers at the Texas A&M Health Science Center College of Medicine and a consortium of leading tuberculosis researchers at Washington University and Stanford University School of Medicine are actively studying tuberculosis infections in live animals using in vivo imaging technology. Caliper's IVIS Spectrum was specifically chosen for its highly sensitive luminescence detection and ability to successfully image, track and quantify tuberculosis infections using fluorescence. The IVIS system enables researchers to visualize the progression of the disease and impact of therapeutic candidates in real time. This rapid evaluation of in vivo efficacy allows researchers to quickly adapt efforts and progress towards effective treatments for the disease.

"We are quite optimistic that this research collaboration will uncover new and promising discoveries in the fight against tuberculosis," said Kevin Hrusovsky, CEO of Caliper Life Sciences. "Caliper's imaging technology has proven to be integral in other discovery efforts for finding new ways and treatments to combat infectious disease. This is a great opportunity to exploit Caliper's imaging technology to make a major impact in this world."

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of leading-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit http://www.caliperLS.com.

Caliper and IVIS are registered trademarks, and Spectrum is a trademark, of Caliper Life Sciences, Inc.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
4. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
8. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
9. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... ... thrilled to announce the ATA 2017 President’s Awards recipients, comprised of organizations ... superior healthcare delivery. , The ATA 2017 President’s Awards recognize individuals ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... Excellence specializes in pelvic conditions and has helped many women become pregnant upon ... a combination of office-based and simple outpatient evaluations. We can provide the ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... for sponsors and CROs to speed clinical development, has released the industry’s ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management ...
(Date:4/25/2017)... (PRWEB) , ... April 25, ... ... based in Newport Beach, California, committed to raising awareness for Duchenne muscular ... results from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting ... Invisalign® in Lutz, FL. With the help of this highly-effective, yet convenient system, ... potential complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, ...
Breaking Medicine News(10 mins):